The stroke clinical program is probably too far ahead of HIE for HIE to be approved first.
So very unlikely to be awarded a priority review voucher.
Still great endorsement/validation from the FDA for the pre-clinical work done to-date.
The stroke clinical program is probably too far ahead of HIE for...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
77.0¢ |
Change
-0.115(13.0%) |
Mkt cap ! $103.2M | |||
| Open | High | Low | Value | Volume |
| 87.0¢ | 87.0¢ | 77.0¢ | $295.6K | 363.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 25209 | 77.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 81.0¢ | 14311 | 2 |
View Market Depth
| Last trade - 15.57pm 05/08/2024 (20 minute delay) ? |
| AGN (ASX) Chart |